Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cripto: a tumor growth factor and more.

Eileen D Adamson1, Gabriella Minchiotti, David S Salomon

  • 1La Jolla Cancer Research Center, The Burnham Institute, La Jolla, California 92037, USA. eadamson@burnham.org

Journal of Cellular Physiology
|February 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Injectable Hydrogel-Based Delivery of Soluble Cripto Protein Enhances Repair After Skeletal Muscle Injury.

ACS biomaterials science & engineering·2026
Same author

Human stem cell-based embryo models: innovation, ethics, and policy.

Human reproduction (Oxford, England)·2026
Same author

Context-dependent effect of glucocorticoid receptor activity shapes ovarian cancer cell plasticity and therapy response.

Molecular cancer·2026
Same author

Non-cell-autonomous control of mouse gastruloid development by the ultra-conserved lncRNA T-UCstem1.

The EMBO journal·2025
Same author

TGF-β1-mediated downregulation of L1CAM in pancreatic ductal adenocarcinoma drives upregulation of collagen 17A1 and MMP2, facilitating tumor invasiveness and metastasis.

Cell death & disease·2025
Same author

The Modulation of Cell Plasticity by Budesonide: Beyond the Metabolic and Anti-Inflammatory Actions of Glucocorticoids.

Pharmaceutics·2025

Cripto, an EGF-CFC gene, drives cancer cell growth and is overexpressed in many tumors. Its roles in development and potential as a cancer marker highlight its significance.

Area of Science:

  • Developmental Biology
  • Cancer Biology
  • Molecular Oncology

Background:

  • Cripto is a growth factor and the first characterized member of the EGF-CFC gene family.
  • EGF-CFC family proteins are unique to vertebrates and play roles in embryonic development.
  • Cripto is overexpressed in various human and mouse carcinomas compared to normal tissues.

Purpose of the Study:

  • To investigate the role of Cripto in cancer development and its potential as a therapeutic target.
  • To explore Cripto's functions in embryonic development and mammary gland morphogenesis.
  • To examine the potential of Cripto as an accessible biomarker for early to mid-stage cancers.

Main Methods:

  • Analysis of Cripto expression in normal and cancerous tissues.

Related Experiment Videos

  • In vitro studies on Cripto's effects on mammary cell proliferation, apoptosis, migration, and differentiation.
  • Review of Cripto's known developmental roles and potential receptor signaling mechanisms.

    • Main Results:

    • Cripto overexpression is observed in breast, cervical, ovarian, gastric, lung, colon, and pancreatic carcinomas.
    • In vitro, Cripto promotes mammary cell proliferation, migration, and inhibits differentiation.
    • Cripto is implicated in embryonic anterior-posterior axis patterning, heart development, and mammary gland development.

    Conclusions:

    • Cripto plays a significant role in tumor development and progression, particularly in mammary tumorigenesis.
    • Cripto's diverse developmental functions suggest complex signaling mechanisms.
    • Further research into Cripto receptors is needed to develop therapeutic strategies and validate its use as a cancer biomarker.